fromArs Technica
3 weeks agoModerna says mRNA flu vaccine sailed through trial, beating standard shot
Moderna's new mRNA-based flu vaccine, mRNA-1010, demonstrated a 27 percent higher efficacy rate in preventing influenza infections compared to the standard flu shot in a trial with nearly 41,000 participants aged 50 and older.
Health